New Drug Mazdutide Explored as Post-Surgery Aid for Severe Obesity
Mazdutide as Adjuvant Therapy Following Sleeve Gastrectomy in Severe Obesity
Background
Globally, severe obesity remains a significant public health challenge, frequently managed through bariatric surgeries such as sleeve gastrectomy, which can induce substantial weight loss and improve metabolic health. However, a subset of patients may experience suboptimal long-term weight management or even weight regain, underscoring a persistent need for enhanced therapeutic strategies to sustain these benefits. This upcoming trial directly addresses the critical knowledge gap in understanding if adjuvant pharmacological therapy can further improve and maintain positive outcomes after bariatric surgery.
Study Design
Population
Patients with severe obesity who have undergone sleeve gastrectomy.
Intervention
Mazdutide as an adjuvant pharmacological therapy.
Outcome
Improved and maintained positive outcomes after bariatric surgery.